THYROID CANCERS

An expert briefly discusses the second-line treatment options for patients with DTC that have progressed on first-line therapy.

A medical professional explains how the size of lung metastases affect the treatment of DTC and clinician decision-making.

Marcia S. Brose, MD, PhD, introduces our second patient case, a 57-year-old man with DTC.

Dr Brose elaborates on treating patients with DTC with lenvatinib, including starting dosage and toxicities/adverse events.

A medical professional discusses Study 211 data and HRQoL analyses for patients with DTC on lenvatinib.

An expert explains the impact of patient age when taking lenvatinib for treatment.

Dr Brose reviews frontline treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Marcia S. Brose, MD, PhD, introduces our first patient case, a 70-year-old woman with differentiated thyroid cancer (DTC).

Yuliya Mikheeva, MD, discusses the phase 2 ANAPLAST-NEO study for patients with anaplastic thyroid cancer.

Vivek Subbiah discusses the phase 1/2 LIBRETTO-001 study which sought to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of selpercatinib in patients with advanced solid tumors.

BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and non–small cell lung cancer, according to a phase 1 study.

In the first interview of this series, Steven G. Waguespack, MD, considers long-term safety and efficacy data on larotrectinib and discusses implications for the treatment landscape for NTRK fusion-positive thyroid cancer.

In this first video of the series, Steven G. Waguespack, MD, of the University of Texas MD Anderson Cancer Center provides an overview of the safety and efficacy of larotrectinib and considers how it has impacted the treatment landscape for NTRK fusion-positive cancers.

A 67-year-old woman presented with a painless lump on her neck. A physical examination showed a palpable, nontender solitary neck mass to the right of the midline.

LIBRETTO-531 succeeds LIBRETTO-001 to continue the study of selpercatinib in patients with multikinase inhibitor therapy-naive RET-mutant advanced medullary thyroid cancer.

Krzysztof J. Misiukiewicz, MD, discusses sequencing of treatments in patients with NTRK-positive thyroid cancer.

Theodore W. Laetsch, MD, discusses which trials were used for the retrospective study of the TRK inhibitor larotrectinib for the treatment of TRK-fusion cancers, including thyroid cancers.

Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.

Yuliya Mikheeva, MD, PhD, of Saint Petersburg State University, discusses the prognosis of patients with anaplastic thyroid cancer.

Extended follow-up of patients in COSMIC-311 showed continued survival benefit and tumor reduction with cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer.

The ATLEP study explored the combination of lenvatinib and pembrolizumab in patients with ATC and poorly differentiated thyroid cancer.

Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the safety profile of larotrectinib in thyroid cancer and other solid tumors.

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, discussed a multiple trial analysis of patients treated with larotrectinib over a median of 24 months.

The panel of experts share their treatment recommendations for a 64-year-old woman with RET wild-type metastatic MTC.

Dr Marcia Brose reviews key efficacy and safety data from the phase 3 ZETA and EXAM clinical trials.

Marcia Brose, MD, presents the case of a 64-year-old woman with RET wild-type metastatic medullary thyroid cancer.

The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.

A subgroup analysis of the phase 3 COSMIC-311 study revealed no key differences in the survival and responses observed with cabozantinib based on the age of patients with RAI-refractory differentiated thyroid cancer.

Lori Wirth, MD, discusses the mechanism of action of pralsetinib and key data from the phase 1/2 ARROW clinical trial.

The panel of experts discuss practical considerations regarding selpercatinib and the LIBRETTO-001 and LIBRETTO-531 clinical trial data.